XPO1 and acute myeloid leukemia: Overexpressed levels of XPO1 lead to enhanced transport of TSP/GRP to the cytoplasm thus, forcing nuclear retention of these proteins is a rational therapeutic strategy of selinexor use in AML [17, 18].